The following is attributed to Acting U.S. Food and Drug Administration (FDA) Commissioner Janet Woodcock, MD. The full press release about the first-ever action by the agency of this sort […]
People of color, those with a higher income, and younger individuals are more likely to participate in clinical trials during their cancer treatment, according to a new study from the […]
Leveraging decentralized clinical trials (DCTs) effectively could help diversify the patient population, create new trial opportunities for sites, and improve quality of operations, says Dr. Pamela Tenaerts, who has just […]
“Systemic racism is as real as any disease,” says Rebecca Marklund in a recent PhRMA blog. “Diversifying clinical trials is a critical path to change and PhRMA, and its members, […]
For decades, the power of the placebo effect was thought to lie in patients’ belief that they were—or at least, could be—receiving a pharmacologically active treatment. A new study by […]